Across TCGA pan-cancer cohorts, PRG2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRG2 data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PRG2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRG2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where PRG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.898	0.631	.002	27	view →
LUAD	DFS	Median	II,III,IV	0.908	0.798	.005	14	view →
HNSC	OS	Median	IV	0.836	0.621	.023	4	view →
PDAC	DFS	Median	All	0.354	0.217	.030	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PRG2 tumor-vs-normal RNA expression · all PRG2 data types